CTLA4 and cancer: Recent years have seen considerable advancements in cancer immunotherapy with the advent of immune checkpoint inhibitors (ICIs) such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1).2